Literature DB >> 12161832

Predictive factors and correlates for pain in postpoliomyelitis syndrome patients.

Helen-Maria Vasiliadis1, Jean-Paul Collet, Stan Shapiro, Adriana Venturini, Daria A Trojan.   

Abstract

OBJECTIVE: To identify predictive and associated factors for muscle and joint pain in postpoliomyelitis syndrome (PPS).
DESIGN: Cross-sectional study design.
SETTING: Postpolio clinics. PARTICIPANTS: Baseline data on 126 PPS patients entered into a multicentered clinical trial.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Adjusted odds ratios were computed by using logistic regression modeling. Patients with or without muscle or joint pain were compared with regard to predictors and associated factors.
RESULTS: In multivariate analyses for muscle pain, significant predictive and associated factors were female gender (P=.0006), longer duration of general fatigue (P=.019), and a lower score on the general health scale (P=.009) of the Medical Outcomes Study 36-Item Short-From Health Survey (SF-36). In multivariate analyses for joint pain, significant predictive and associated factors were female gender (P<.003), longer latency (duration of stability after polio; P=.008), younger age at interview (P<.002), greater weakness at acute polio (P<.07), weaker lower-extremity muscle strength (P<.04), and a lower SF-36 general health scale score (P<.02).
CONCLUSIONS: Women are more likely to report muscle and joint pain in PPS. Greater initial motor unit involvement and lower-extremity weakness may be additional important factors for determining joint pain. Both muscle and joint pain are associated with reductions in quality of life. Copyright 2002 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation

Entities:  

Mesh:

Year:  2002        PMID: 12161832     DOI: 10.1053/apmr.2002.33727

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  9 in total

1.  Pain in persons with postpolio syndrome: frequency, intensity, and impact.

Authors:  Brenda L Stoelb; Gregory T Carter; Richard T Abresch; Sophia Purekal; Craig M McDonald; Mark P Jensen
Journal:  Arch Phys Med Rehabil       Date:  2008-10       Impact factor: 3.966

2.  Analysis of long-standing nociceptive and neuropathic pain in patients with post-polio syndrome.

Authors:  Lars Werhagen; Kristian Borg
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

3.  [Postpolio syndrome. Neurologic and psychiatric aspects].

Authors:  M-A Weber; P Schönknecht; J Pilz; B Storch-Hagenlocher
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

4.  Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis.

Authors:  Tiina Rekand; Arne Gramstad; Christian A Vedeler
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

5.  Post-Polio Syndrome.

Authors:  Bruk Jubelt
Journal:  Curr Treat Options Neurol       Date:  2004-03       Impact factor: 3.598

6.  Psychosocial factors and adjustment to pain in individuals with postpolio syndrome.

Authors:  Adam T Hirsh; Amy E Kupper; Gregory T Carter; Mark P Jensen
Journal:  Am J Phys Med Rehabil       Date:  2010-03       Impact factor: 2.159

7.  The effects of a home-based arm ergometry exercise programme on physical fitness, fatigue and activity in polio survivors: protocol for a randomised controlled trial.

Authors:  Deirdre Murray; Dara Meldrum; Roisin Moloney; Anna Campion; Frances Horgan; Orla Hardiman
Journal:  BMC Neurol       Date:  2012-12-13       Impact factor: 2.474

Review 8.  Effectiveness of Intravenous Immunoglobulin for Management of Pain in Patients with Postpolio Syndrome.

Authors:  Min Cheol Chang; Jin-Sung Park; Jong-Moon Hwang; Donghwi Park
Journal:  Pain Res Manag       Date:  2021-03-20       Impact factor: 3.037

9.  PAIN IN POST-POLIO SYNDROME: A SEPARATE PAIN ENTITY?

Authors:  Evert Christiaan Boshuis; Eva Melin; Kristian Borg
Journal:  J Rehabil Med Clin Commun       Date:  2022-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.